Literature DB >> 29468771

Home blood-pressure monitoring in a hypertensive pregnant population.

H Perry1,2, E Sheehan2, B Thilaganathan1,2, A Khalil1,2.   

Abstract

OBJECTIVE: The majority of patients with chronic or gestational hypertension do not develop pre-eclampsia. Home blood-pressure monitoring (HBPM) has the potential to offer a more accurate and acceptable means of monitoring hypertensive patients during pregnancy compared with traditional pathways of frequent outpatient monitoring. The aim of this study was to determine whether HBPM reduces visits to antenatal services and is safe in pregnancy.
METHODS: This was a case-control study of 166 hypertensive pregnant women, which took place at St George's Hospital, University of London. Inclusion criteria were: chronic hypertension, gestational hypertension or high risk of developing pre-eclampsia, no significant proteinuria (≤ 1+ proteinuria on dipstick testing) and normal biochemical and hematological markers. Exclusion criteria were maternal age < 16 years, systolic blood pressure > 155 mmHg or diastolic blood pressure > 100 mmHg, significant proteinuria (≥ 2+ proteinuria on dipstick testing or protein/creatinine ratio > 30 mg/mmol), evidence of small-for-gestational age (estimated fetal weight < 10th centile), signs of severe pre-eclampsia, significant mental health concerns or insufficient understanding of the English language. Pregnant women in the HBPM group were taught how to measure and record their blood pressure using a validated machine at home and attended every 1-2 weeks for assessment depending on clinical need. The control group was managed as per the local protocol prior to the implementation of HBPM. The two groups were compared with respect to number of visits to antenatal services and outcome.
RESULTS: There were 108 women in the HBPM group and 58 in the control group. There was no difference in maternal age, parity, body mass index, ethnicity or smoking status between the groups, but there were more women with chronic hypertension in the HBPM group compared with the control group (49.1% vs 25.9%, P = 0.004). The HBPM group had significantly fewer outpatient attendances per patient (6.5 vs 8.0, P = 0.003) and this difference persisted when taking into account differences in duration of monitoring (0.8 vs 1.6 attendances per week, P < 0.001). There was no difference in the incidence of adverse maternal, fetal or neonatal outcome between the two groups.
CONCLUSION: HBPM in hypertensive pregnancies has the potential to reduce the number of hospital visits required by patients without compromising maternal and pregnancy outcomes.
Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  blood pressure; home monitoring; pre-eclampsia; pregnancy; smartphone application

Mesh:

Year:  2018        PMID: 29468771     DOI: 10.1002/uog.19023

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  10 in total

1.  Self-monitoring of blood pressure among women with hypertensive disorders of pregnancy: a systematic review.

Authors:  Ping Teresa Yeh; Dong Keun Rhee; Caitlin Elizabeth Kennedy; Chloe A Zera; Briana Lucido; Özge Tunçalp; Rodolfo Gomez Ponce de Leon; Manjulaa Narasimhan
Journal:  BMC Pregnancy Childbirth       Date:  2022-05-31       Impact factor: 3.105

2.  Association of maternal home blood pressure trajectory during pregnancy with infant birth weight: the BOSHI study.

Authors:  Noriyuki Iwama; Mari S Oba; Michihiro Satoh; Takayoshi Ohkubo; Mami Ishikuro; Taku Obara; Satomi Sasaki; Masatoshi Saito; Yoshitaka Murakami; Shin-Ichi Kuriyama; Nobuo Yaegashi; Kazuhiko Hoshi; Yutaka Imai; Hirohito Metoki
Journal:  Hypertens Res       Date:  2020-03-10       Impact factor: 3.872

3.  Out-of-office blood pressure measurement for the diagnosis of hypertension in pregnancy: Survey of Canadian Obstetric Medicine and Maternal Fetal Medicine specialists.

Authors:  K C Tran; J Potts; J Robertson; K Ly; N Dayan; N A Khan; W Chan
Journal:  Obstet Med       Date:  2019-01-13

Review 4.  Cardiovascular System in Preeclampsia and Beyond.

Authors:  Basky Thilaganathan; Erkan Kalafat
Journal:  Hypertension       Date:  2019-03       Impact factor: 10.190

5.  Understanding the Needs of a Mobile Phone-Based Telemonitoring Program for Pregnant Women at High Risk for Pre-Eclampsia: Interpretive Qualitative Description Study.

Authors:  Anam Shahil Feroz; Kristina De Vera; Nadia D Bragagnolo; Sarah Saleem; Zulfiqar Bhutta; Emily Seto
Journal:  JMIR Form Res       Date:  2022-02-24

6.  Home Blood Pressure Measurement and Self-Interpretation of Blood Pressure Readings During Pregnancy: Hy-Result e-Health Prospective Study.

Authors:  Nicolas Postel-Vinay; Jiali-Delphine Shao; Anne Pinton; Aude Servais; Nicole Gebara; Laurence Amar
Journal:  Vasc Health Risk Manag       Date:  2022-04-15

7.  Home blood pressure monitoring in the diagnosis and treatment of hypertension in pregnancy: a systematic review and meta-analysis.

Authors:  Karen Tran; Raj Padwal; Nadia Khan; Mary-Doug Wright; Wee Shian Chan
Journal:  CMAJ Open       Date:  2021-06-15

8.  Pregnancy hypertension diagnosis and care in COVID-19 era and beyond.

Authors:  L A Magee; A Khalil; P von Dadelszen
Journal:  Ultrasound Obstet Gynecol       Date:  2020-07       Impact factor: 8.678

9.  Exploring perspectives, preferences and needs of a telemonitoring program for women at high risk for preeclampsia in a tertiary health facility of Karachi: a qualitative study protocol.

Authors:  Anam Feroz; Sarah Saleem; Emily Seto
Journal:  Reprod Health       Date:  2020-09-15       Impact factor: 3.223

Review 10.  Exploring the Use of Telemonitoring for Patients at High Risk for Hypertensive Disorders of Pregnancy in the Antepartum and Postpartum Periods: Scoping Review.

Authors:  Maria Aquino; Sarah Munce; Janessa Griffith; Maureen Pakosh; Mikayla Munnery; Emily Seto
Journal:  JMIR Mhealth Uhealth       Date:  2020-04-17       Impact factor: 4.773

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.